News | May 23, 2021
Orchid Pharma Q4FY21 consolidated loss at Rs. 24.72 Cr
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The agreement will help ensure wider reach and access to patients in India
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Essential medicines were made available to more than 150 countries around the world during the pandemic
Subscribe To Our Newsletter & Stay Updated
